Carotid endarterectomy for symptomatic carotid stenosis
Abstract
Background
Stroke is the third leading cause of death and the most common cause of long‐term disability. Severe narrowing (stenosis) of the carotid artery is an important cause of stroke. Surgical treatment (carotid endarterectomy) may reduce the risk of stroke, but carries a risk of operative complications. This is an update of the Cochrane Review, originally published in 1999, and most recently updated in 2011.
Objectives
To determine the balance of benefit versus risk of endarterectomy plus best medical management compared with best medical management alone, in people with a recent symptomatic carotid stenosis (i.e. transient ischaemic attack (TIA) or non‐disabling stroke).
Search methods
We searched the Cochrane Stroke Group Trials Register (last searched in July 2016), CENTRAL (2016, Issue 7), MEDLINE (1966 to July 2016), Embase (1990 to July 2016), Web of Science Core Collection, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (ICTRP) portal, and handsearched relevant journals and reference lists.
Selection criteria
We included randomised controlled trials.
Data collection and analysis
Two review authors independently selected studies, assessed risk of bias, and extracted the data.
Main results
We included three trials involving 6343 participants. As the trials differed in the methods of measurement of carotid stenosis and in the definition of stroke, we did a pooled analysis of individual patient data on 6092 participants (35,000 patient years of follow‐up), after reassessing the carotid angiograms and outcomes from all three trials using the primary electronic data files, and redefined outcome events where necessary, to achieve comparability.
On re‐analysis, there were no significant differences between the trials in the risks of any of the main outcomes in either of the treatment groups, or in the effects of surgery. Surgery increased the five‐year risk of ipsilateral ischaemic stroke in participants with less than 30% stenosis (N = 1746, risk ratio (RR) 1.27, 95% confidence interval (CI) 0.80 to 2.01), had no significant effect in participants with 30% to 49% stenosis (N = 1429, RR 0.93, 95%CI 0.62 to 1.38), was of benefit in participants with 50% to 69% stenosis (N = 1549, RR 0.84, 95%CI 0.60 to 1.18), and was highly beneficial in participants with 70% to 99% stenosis without near‐occlusion (N = 1095, RR 0.47, 95%CI 0.25 to 0.88). However, there was no evidence of benefit (N = 271, RR 1.03, 95%CI 0.57 to 1.84) in participants with near‐occlusions. Ipsilateral ischaemic stroke describes insufficient blood flow to the cerebral hemisphere, secondary to same side severe stenosis of the internal carotid artery.
Authors' conclusions
Endarterectomy was of some benefit for participants with 50% to 69% symptomatic stenosis (moderate‐quality evidence), and highly beneficial for those with 70% to 99% stenosis without near‐occlusion (moderate‐quality evidence). We found no benefit in people with carotid near‐occlusion (high‐quality evidence).
PICO
Plain language summary
Carotid surgery in patients who have symptoms with narrowing of the carotid artery
Question: What are the benefits of surgical removal of the fatty deposits and blood clots from inside the carotid artery wall (carotid endarterectomy) for patients who have recently (within four to six months) had symptoms due to carotid stenosis (narrowing of the artery that supplies blood to the brain).
Background: Strokes cause long‐term disability and death. The chances of dying from the first stroke are 15% to 35%, and increase to 69% in subsequent strokes, which often occur within one year of the first attack. Carotid endarterectomy may reduce the risk of stroke, but carries a risk of complications immediately before, after, and during the operation, including disabling stroke and death. There is a 7% risk of stroke and death within 30 days of and endarterectomy, which includes an ocular (eye) or cerebral (brain) stroke, with symptoms lasting longer than 24 hours.
Study characteristics: This review identified three randomised controlled trials (6343 participants randomised), which compared carotid surgery with no carotid surgery (i.e. best medical therapy plus surgery versus best medical therapy alone) in participants with carotid stenosis and recent transient ischaemic attacks (TIA) or minor ischaemic strokes in the territory of that artery. The trials were carried out in Europe, USA, and Canada and included some centres in Israel, South Africa, and Australia. The gender ratio of participants was 2.6:1 (72% men and 28% women); 90% of participants were younger than 75 years old.
The results of the three trials were initially conflicting because they differed in how they measured carotid stenosis and how they defined the outcomes. To address this discrepancy, we reassessed the patient data using the same methods and definitions, so results could be compared.
Key results: The results of the review are current up to July 2016. Results showed that older male participants with 70% to 99% stenosis, without occlusion, and recent (within two weeks) TIA or stroke, had the most benefit from surgery, assuming they were well enough for surgery, and their surgeons had a record of low complication rates (less than 7% risk of stroke and death). Carotid endarterectomy also benefited participants with 50% to 99% carotid stenosis and symptoms. For participants whose carotid artery was nearly occluded, benefit was uncertain in the long term. Surgery tended to harm participants with less than 30% stenosis.
The second European Carotid Surgery Trial, which is currently recruiting participants, is exploring whether a lipid lowering agent (statin) might be a better choice than carotid endarterectomy to prevent ischaemic stroke in ipsilateral carotid stenosis, which may benefit those who did not benefit from surgery in these trials.
Quality of the evidence: We found the evidence to be high quality for near occlusion and less than 30% carotid stenosis; and moderate quality for 50% to 99% carotid stenosis for any stroke or operative death, as well as ipsilateral ischaemic stroke and any operative stroke or death outcome.
Authors' conclusions
Summary of findings
| Carotid endarterectomy for symptomatic carotid stenosis | ||||||
| Patients or population: people with carotid stenosis and recent transient ischaemic attacks (TIA) or minor ischaemic strokes in the territory of that artery Settings: in hospitals with carotid centres1 Intervention: best medical therapy with carotid surgery2,3 Comparison: best medical therapy without carotid surgery2 | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | Number of (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Best medical treatment alone | Best medical treatment with carotid surgery | |||||
| Any stroke or operative death | Near occlusion | RR 0.95 (0.59 to 1.53) | 271 (2 studies) | ++++ High4 | None of these RCTs could be blinded for surgeons or patients due to the nature of the intervention. | |
| 22 per 100 | 20 per 100 | |||||
| 70% to 99% carotid stenosis | RR 0.53 (0.42 to 0.67) | 1095 (3 studies) | +++Ο Moderate5 | |||
| 29 per 100 | 15 per 100 | |||||
| 50% to 69% carotid stenosis | RR 0.77 (0.63 to 0.94) | 1549 (3 studies) | +++Ο Moderate5 | |||
| 23 per 100 | 18 per 100 | |||||
| 30% to 49% carotid stenosis | RR 0.97 (0.79 to 1.19) | 1429 (2 studies) | ++++ High4 | |||
| 21 per 100 | 20 per 100 | |||||
| < 30% carotid stenosis | RR 1.25 (0.99 ‐ 1.56) | 1746 (2 studies) | ++++ High4 | |||
| 14 per 100 | 17 per 100 | |||||
| Ipsilateral ischaemic stroke, and any operative stroke or death | Near occlusion | RR 1.03 (0.57 to 1.84) | 271 (2 studies) | ++++ High4 | None of these RCTs could be blinded for surgeons or patients due to the nature of the intervention. | |
| 15 per 100 | 15 per 100 | |||||
| 70% to 99% carotid stenosis | RR 0.47 (0.25 to 0.88) | 1095 (3 studies) | +++Ο Moderate5 | |||
| 23 per 100 | 10 per 100 | |||||
| 50% to 69% carotid stenosis | RR 0.84 (0.60 to 1.18) | 1549 (3 studies) | +++Ο Moderate5 | |||
| 15 per 100 | 12 per 100 | |||||
| 30% to 49% carotid stenosis | RR 0.93 (0.62 to 1.38) | 1429 (2 studies) | ++++ High4 | |||
| 15 per 100 | 13 per 100 | |||||
| < 30% carotid stenosis | RR 1.27 (0.80 to 2.01) | 1746 (2 studies) | ++++ High4 | |||
| 9 per 100 | 11 per 100 | |||||
| *The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the intervention group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) | ||||||
| 1 ECST recruited from 100 centres in 14 European countries, NASCET from 106 centres mainly in the USA and Canada, but including some centres in Europe, Israel, South Africa and Australia, and the VACSP trial from 16 Veterans Affairs medical centres in the USA 2 The recommended dose of aspirin for best medical treatment was 1300 mg in NASCET, 325 mg in the VACSP trial, and unspecified in ECST 3 The median time from randomisation to trial surgery was two days in the VACSP trial, three days in NASCET and 14 days in ECST. 4 All 2 studies (ECST, NASCET) are unconfounded truly randomised controlled trials and conducted on an intention to treat principle with adequate concealment, Few patients were lost to follow up in any of these studies (follow up 99.8‐100%) 5 All 3 studies (ECST, NASCET, VACSP) are unconfounded truly randomised controlled trials and conducted on an intention‐to‐treat principle. However, the allocation concealment was not described in one trial (VACSP). In addition, ECST and NASCET were both stopped after appropriately pre‐specified interim analyses showed that the trial stopping rules had been met. VACSP was also stopped with 193 participants after the results of ECST and NASCET were announced. | ||||||
Background
Description of the condition
Stroke is the third leading cause of death and probably the most important cause of long‐term disability (Bonita 1992). The case fatality rate is between 15% and 35% with the first attack, and rises to 65% for subsequent strokes. The majority of recurrences occur within one year, and in the same anatomic region as the first stroke (Mohr 1978; Sacco 1982; Soltero 1978). Disability in survivors is a burden to the patients, their families, and to society. Eighty‐five per cent of strokes are ischaemic (Bamford 1990). Fieschi 1989 found that in conscious people with an acute ischaemic stroke requiring admission to a stroke unit, 76% had angiographic evidence of complete occlusion of the internal carotid artery, the middle cerebral artery, or one of its branches. The majority of these occlusions were thought to be embolic and of cerebrovascular origin.
Description of the intervention
Atherosclerotic plaques can rupture and lead to thrombosis and emboli, which can cause stroke if it occurs in a carotid artery (Eliasziw 1994). Carotid endarterectomy is a surgical procedure to remove the endothelium and atherosclerotic plaque from inside the carotid artery wall. This has been proven to reduce the risk of stroke in certain groups of people. Two techniques have been described for carotid endarterectomy. In a standard endarterectomy, the most popular technique, carotid plaque is removed by a longitudinal arteriotomy. An eversion endarterectomy is performed through an oblique transection of the internal carotid artery from the common carotid artery, endarterectomy by eversion of the internal carotid artery, and reimplantation of the internal carotid artery on the common carotid artery.
How the intervention might work
As previously stated, atherosclerotic plaque can cause embolic stroke. Since carotid endarterectomy removes plaque from the carotid artery, the source of a cerebral embolism is also removed. In addition, the procedure removes the stenotic part of the carotid artery, so blood flow to the brain can be increased.
Why it is important to do this review
Carotid endarterectomy was introduced in the 1950s and increasing numbers of people have undergone this procedure over the last three decades (from 14,000 performed in the USA in 1971 to 107,000 in 1985; Pokras 1988). In 1985, the Extracranial/Intracranial (EC/IC) Bypass Study showed no benefit for this form of surgery, increasing uncertainties about the value of carotid endarterectomy (EC/IC Bypass 1985). By 1989, the number of carotid endarterectomies performed in North America had declined to 70,000 (Dyken 1993; Hsia 1992). These uncertainties led to large randomised controlled trials (RCTs) assessing the efficacy of the procedure in different clinical settings.
There have been five randomised controlled trials of endarterectomy in people with a recent symptomatic carotid stenosis. The first two studies were small, performed over 30 years ago, included a high proportion of people with non‐carotid symptoms, and did not stratify results by severity of the stenosis (Fields 1968; Shaw 1984). In 1991, the Veterans Affairs trial reported a non‐significant trend in favour of surgery (VACSP 1991), but this trial was stopped early when the two largest trials, the European Carotid Surgery Trial (ECST 1998), and the North American Symptomatic Carotid Endarterectomy Trial (NASCET 1991), reported their initial results. The final reports for ECST 1998 and NASCET 1991 were published in 1998. ECST 1998 reported benefit from surgery only in participants with 80% to 99% stenosis, and further limited this to 90% to 99% stenosis in women. In contrast, NASCET 1991 reported significant benefit from surgery in participants with 50% to 99% stenosis. In the previous version of this review, an attempt was made to reconcile and pool these apparently conflicting results (Rerkasem 2011). The differences between the trial results were partly due to differences in the methods of measurement of the degree of carotid stenosis on the pre‐randomisation catheter angiograms: the method used in ECST 1998 produced higher values than the method used in the NASCET 1991 and VACSP 1991 trials. There were also other differences, such as in the definitions of outcome events. Only by detailed re‐analysis of the individual patient data and reassessment of the original angiograms can the results be properly compared or combined. In this version of the review, we have also included a pooled analysis of individual patient data from the three largest trials, in which the original angiograms were reassessed and analyses done, using the same method of measurement of stenosis and the same definitions of outcomes.
However, the overall trial results may not help patients and clinicians in making decision about surgery. It would be useful to be able to identify in advance, and operate on, only those people with a high risk of stroke on medical treatment alone, but relatively low operative risk. In addition to the degree of carotid stenosis, there are several other factors that might influence the risks and benefits of surgery, including the delay between presenting symptoms and surgery, and certain clinical and angiographic characteristics (Alamowitch 2001; Benavente 2001; Eliasziw 1994; Henderson 2000; Kappelle 1999; Morgenstern 1997; Rothwell 1997; Rothwell 1999). Neither ECST 1998 nor NASCET 1991 were powered to determine the effect of surgery in subgroups. Subgroup analyses of pooled individual patient data from ECST 1998 and NASCET 1991 have greater power to determine subgroup treatment interaction reliably and therefore, several such clinically important analyses have been added in this updated version.
Objectives
To determine the balance of benefit versus risk of endarterectomy plus best medical management compared with best medical management alone in people with a recent symptomatic carotid stenosis (i.e. transient ischaemic attack (TIA) or non‐disabling stroke).
Methods
Criteria for considering studies for this review
Types of studies
We included unconfounded truly randomised controlled trials (RCTs).
Types of participants
People with carotid stenosis and recent transient ischaemic attacks (TIA) or minor ischaemic strokes in the territory of that artery.
Types of interventions
Unconfounded comparison of carotid surgery with no carotid surgery (i.e. best medical therapy plus surgery versus best medical therapy alone).
Types of outcome measures
Primary outcomes
-
Five‐year cumulative any stroke or operative death.
-
Five‐year cumulative ipsilateral ischaemic stroke, or operative stroke, or operative death.
The five‐year cumulative risk is the summative risk of all patients between recruitment and index outcome in five years.
We defined trial surgery as the first carotid endarterectomy performed in participants who were randomised to surgery. We defined operative risk as any stroke or death that occurred within 30 days of trial surgery. Operative death included all deaths within 30 days of trial surgery. We defined the symptomatic carotid artery as in the original trials.
Ipsilateral ischaemic stroke describes insufficient blood flow to the cerebral hemisphere secondary to the same side occlusion, or severe stenosis of the internal carotid artery in participants.
Secondary outcomes
-
Five‐year cumulative disabling or fatal ipsilateral ischaemic, or operative stroke, and operative death.
Search methods for identification of studies
See the 'Specialized register' section in the Cochrane Stroke Group module. We did not use any language restrictions in the searches; we arranged translation of all possibly relevant publications where necessary.
Electronic searches
We searched the Cochrane Stroke Group's Trials Register, which was last searched by the Managing Editor in July 2016. In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 7) in the Cochrane Library (searched 26 July 2016; Appendix 1), MEDLINE (1966 to 26 July 2016; Appendix 2), and Embase (1980 to 26 July 2016; Appendix 3). We also searched the Web of Science Core Collection, and other trials registers, including ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) portal (Higgins 2016).
Having identified the two major studies in this area, we used a post‐hoc search strategy of ECST (text word) or European Carotid Surgery Trial (text word) or NASCET (text word) or North American Symptomatic Carotid Endarterectomy Trial (text word) in the Cochrane Central Register of Controlled Trials and in the MEDLINE database from 1990 to 26 July 2016, in the hope of identifying previously unretrieved publications from these trials.
Searching other resources
In an effort to identify further published, unpublished and ongoing trials:
-
we handsearched the following journals:
-
Annals of Surgery (2010 to July 2016);
-
Annals of Vascular Surgery (2010 to July 2016);
-
Cardiovascular Surgery (now Vascular) (2010 to July 2016);
-
European Journal of Vascular Surgery (now European Journal of Vascular and Endovascular Surgery) (1988 to July 2016);
-
Journal of Vascular Surgery (2010 to July 2016);
-
Stroke (2010 to July 2016),
-
-
we reviewed the reference lists of all relevant studies.
Data collection and analysis
Two review authors (SO, KR) independently collected data. We collected the details of methods, participants, setting, context, interventions, outcomes, results, publications, and investigators. We performed meta‐analysis using RevMan 5 (RevMan 2014).
Selection of studies
Both review authors independently read the titles and abstracts of the records obtained from the electronic searches and excluded obviously irrelevant studies. We obtained the full texts of the remaining papers, and the same authors independently selected studies for inclusion, based on the predefined criteria. We resolved any disagreements through discussion.
Data extraction and management
One review author (SO) selected those trials that met the inclusion criteria and another review author (KR) independently reviewed these decisions. We resolved all disagreements through discussion. We extracted details of the method of randomisation, the blinding of outcome assessments, losses to follow‐up, and cross‐overs and exclusions after randomisation from the publications. We also compared participant characteristics (age, sex, vascular risk factors, indication for surgery) and details of the operation (type of cerebral monitoring, use of carotid patching, anaesthetic technique, use of perioperative antiplatelet therapy) between the treatment groups in each trial.
Assessment of risk of bias in included studies
One review author (SO) assessed the risk of bias and another review author (KR) independently reviewed these decisions. We resolved all disagreements through discussion. We assessed risk of bias (high risk, low risk, unclear risk) using the Cochrane 'Risk of bias' tool as described in the Cochrane Handbook for Systematic Reviews of Interventions and reported the details in the 'Risk of bias' tables (Higgins 2011). These risks of bias included random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding outcome assessment (detection bias), and incomplete outcome data (attrition bias).
Measures of treatment effect
We measured the treatment effect in the following outcomes within five years of randomisation: stroke, death, ipsilateral ischaemic stroke, disabling or fatal ipsilateral ischaemic stroke, stroke and death within 30 days after carotid endarterectomy.
Unit of analysis issues
We extracted details of all the outcome events. Some studies included participants who had bilateral operations, but only reported the number of participants in each group, and not the number of arteries. Unit of analysis issues originate when bilateral carotid arteries on the same participants are studied in a trial and such highly correlated data are regarded as independent, when multiple assessments of the same outcome are presented, or both. We recorded whether trials presented outcomes in relation to an artery, a participant, or as multiple (bilateral) carotid arteries on the same participant.
When a cluster‐randomised trial has been conducted and correctly analysed, effect estimates and their standard errors may be meta‐analysed using the generic inverse variance method in Review Manager 5 (RevMan 2014). If the randomisation was performed on the individuals rather than the clusters. we approximated the correct analyses using data suggested in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011)
-
the number of clusters (or groups) randomised to each intervention group, or the average (mean) size of each cluster;
-
the outcome data, ignoring the cluster design, for the total number of individuals (for example, number or proportion of individuals with events, or means and standard deviations); and
-
an estimate of the intracluster (or intraclass) correlation coefficient (ICC).
Dealing with missing data
When data were missing, we contacted the corresponding author or co‐author through the address given in the publication. If this information was not available, we searched for the study group via the Internet and contacted them for missing information.
Assessment of heterogeneity
We assessed heterogeneity between study results using the I² statistic (Higgins 2003). We examined the percentage of total variations across the studies due to heterogeneity, rather than to chance.
We used I² results for quantifying inconsistency across studies. Values of I2 over 75% indicate a considerable level of heterogeneity. We also tested heterogeneity between trial results using the standard Chi2 test. We considered a P value < 0.05 to be statistically significant.
Assessment of reporting biases
We performed an extensive search and are confident that we have identified all major relevant trials. We also contacted experts in this field. We searched for trials published in all languages and we arranged translation of all possibly relevant publications when required. We had planned to use funnel plots to assess publication bias when more than 10 studies were included (Sterne 2011). However, if there were insufficient studies to conduct this analysis, we had planned to compare the study protocols with the final study reports to evaluate selective reporting of outcomes.
Data synthesis
We included all participants included in the final analysis of the results of the original trials in the combined analysis, using the Mantel Haenszel method (fixed‐effect). We stratified the main analyses according to the stenosis groups that were used in the NASCET 1991 trial (less than 30%, 30% to 49%, 50% to 69%, 70% to 99%), and analysed near‐occlusions separately (Rothwell 2003).
We performed all analyses of the effect of surgery on an intention‐to‐treat basis according to the randomised treatment allocation. We assessed significance of the differences between treatment groups by the log rank test stratified by study. We determined estimates of the absolute treatment effect (and 95% confidence intervals) at five‐year follow‐up from the Kaplan‐Meier event‐free survival curves. We tested significance of the differences in baseline data between trials and treatment groups using the Chi² test or Student’s t‐test, as appropriate. We used the Cochrane Review Manager 5 software (RevMan 2014) and SPSS for Windows version 10.0 for all analyses (SPSS 1999). We used the fixed‐effect model for meta‐analysis in the absence of clinical, methodological, and statistical heterogeneity. If the I² statistic was greater than zero, we also applied a random‐effects model to see whether the conclusions differed, and we noted any difference. If pooling was not possible or appropriate, we had planned to present a narrative summary (Deeks 2011).
GRADE and 'Summary of findings' table
We created summary of findings Table for the main comparison with GRADE Profiler 3.6 (GRADEpro 2015), which imports data from RevMan 5 (RevMan 2014). This table presents the results and the quality of the evidence of the main outcomes, using the GRADE system, which classifies the quality of evidence as high, moderate, low, and very low (Schünemann 2011).
Pooling of individual patient data
We obtained the original individual patient data for the three included trials. We merged data on presenting events, baseline clinical, brain imaging, and angiographic characteristics, surgical and anaesthetic technique, and follow‐up into a single composite database. We gave detailed consideration to the definitions of each variable used in the original trials. Where definitions were identical, we merged comparable data. Where possible, we resolved differences in definitions of variables between studies by reconstructing definitions to achieve comparability.
Reassessment of carotid angiograms and identification of near‐occlusions
We collected all ECST 1998 and NASCET 1991 pre‐randomisation angiograms and reviewed them centrally for a previous version of this review (Rerkasem 2011). The analyses could, therefore, be consistently stratified by the degree of symptomatic carotid stenosis. As the first version of this review was performed without reclassifying angiograms, it was difficult to compare the results between studies (ECST 1998; NASCET 1991; VACSP 1991). This was due to different grading of the carotid stenosis used by the trials. One observer, who was blind to outcome events, re‐measured the 3018 ECST 1998 angiograms and re‐calculated the degree of stenosis by the method used in NASCET 1991 and VACSP 1991. The NASCET 1991 method was based on measurement of the minimum residual lumen at the point of maximum stenosis and the diameter of the normal internal carotid artery well beyond the carotid bulb, where the walls of the artery were parallel. We assessed observer agreement between one observer and the NASCET 1991 principal neuroradiologist on 120 randomly selected angiograms (60 from ECST 1998 and 60 from NASCET 1991).
The degree of stenosis could not be calculated by the method used in the NASCET 1991 and VACSP 1991 trials on angiograms, in which the post‐stenotic internal carotid artery (ICA) was narrowed to the point of near occlusion. In the original NASCET 1991 reports, these 'near‐occlusions' were identified and assigned as 95% stenosis for the purpose of analysis. Therefore, we identified near‐occlusions during the reassessment of the ECST 1998 angiograms for this review. We used the previously reported NASCET 1991 angiographic criteria for near‐occlusion: severe stenosis with evidence of reduced flow in the distal ICA (delayed arrival of contrast into the distal ICA, or evidence of collateral flow of contrast towards the symptomatic cerebral hemisphere from other arterial territories, or both) and evidence of narrowing of the post‐stenotic ICA (lumen diameter similar to, or less than, the ipsilateral external carotid artery, and less than the contralateral ICA). To ensure comparability with NASCET 1991, the NASCET 1991 principal neuroradiologist assessed all potential near‐occlusions identified in ECST 1998. The VACSP 1991 trial angiograms were not available for further review, and were not included in the analysis of near‐occlusions. For the purpose of analysis, all VACSP 1991 trial angiograms with stenosis of 70% or more were considered to have stenosis of 70% or more without near‐occlusion.
Redefinition of outcome events
In the NASCET 1991 and VACSP 1991 trials, a stroke outcome was defined as a cerebrovascular event with symptoms lasting longer than 24 hours. ECST 1998 had recorded all such events, but had confined analysis to events with symptoms that lasted for at least seven days. In the NASCET 1991 and VACSP 1991 trials, retinal infarcts were included as stroke outcomes. In ECST 1998, they were not, although they were recorded. For the purpose of the combined analyses, we defined stroke as any cerebral or retinal event with symptoms lasting longer than 24 hours. ECST 1998 and NASCET 1991 used the modified Rankin Scale to define disabling stroke. The VACSP 1991 trial used an equivalent 'in‐house' scale. Disability was defined at three months after the stroke in NASCET 1991, at six months in ECST 1998, and at the next routine follow‐up assessment in the VACSP 1991 trial. For the purposes of the combined analysis, we defined disabling stroke as a stroke that resulted in a Rankin score of three or more, or equivalent, at these points of follow‐up.
Subgroup analysis and investigation of heterogeneity
To reduce the risk of chance findings, the collaborators met in 1999, prior to the pooling of data, to predefine a limited number of subgroups on the basis of potential clinical importance and availability in both trials (Rothwell 2004). These subgroups were derived from the risk factors that had been predefined at the beginning of NASCET 1991. The following subgroup analyses were specified:
-
male versus female;
-
age (less than 65 years old versus 65 to 74 years old versus 75+ years);
-
time from most recent symptomatic ischaemic event to randomisation (less than two weeks, two to four weeks, four to 12 weeks, more than two weeks);
-
primary ischaemic event in the territory of the stenosed artery during the six months prior to randomisation; this was defined in a hierarchical manner as hemispheric stroke versus hemispheric TIA but no stroke versus retinal event only;
-
diabetes versus no diabetes;
-
irregular or ulcerated symptomatic carotid plaque versus smooth plaque on the pre‐randomisation angiogram; and
-
contralateral carotid occlusion versus no occlusion.
To identify any important but unexpected treatment effect modifiers, we identified seven post‐hoc subgroup variables, on the basis that comparable baseline data were available from the two trials:
-
duration of cerebral TIA (one hour or less versus more than one hour);
-
previous TIA or stroke (i.e. events prior to the six‐month eligibility period as well as recent events);
-
previous myocardial infarction;
-
previous angina;
-
treated hypertension (defined as that requiring a blood‐pressure‐lowering drug);
-
treated hyperlipidaemia (defined as that requiring a dietary change or cholesterol‐lowering drug); and
-
regular smoking during the previous year.
We first assessed the relationship between each subgroup variable and: 1) the risk of ipsilateral carotid territory ischaemic stroke in participants randomised to medical treatment (medical risk); and 2) any stroke or death which occurred within 30 days after trial surgery (perioperative risk). We determined the five‐year cumulative risks of ipsilateral ischaemic stroke in relation to each subgroup variable. We also determined the associations in a Cox proportional hazards model with adjustment for source trial and degree of carotid stenosis.
Determination of the significance of treatment effect modification by subgroup is complicated by the differential changes in event rate with time in the two treatment groups. Nevertheless, we initially performed a Cox proportional hazard model with treatment allocation, a source study term, degree of stenosis, a subgroup by treatment allocation interaction term, and a stenosis by treatment allocation interaction term. We also performed an additional test for trend for the analysis of the effects of age and time from last event to randomisation. To maximise statistical power to detect treatment effect modification by subgroup, we performed these analyses of subgroup by treatment interaction across all degrees of stenosis. We considered it unlikely that the direction of any treatment effect modification by subgroup would differ qualitatively with degree of stenosis. However, we performed a further Cox model to test the significance of the three‐way interaction between stenosis, subgroup, and treatment allocation.
Sensitivity analysis
When the decisions for the process undertaken in this systematic review were somewhat arbitrary or unclear, we undertook sensitivity analyses. For example, we performed both fixed‐effect and random‐effects meta‐analyses to evaluate the consistency of the results, or we compared pooled estimates of all studies' results with the results of the studies excluded because of higher risk of bias.
Results
Description of studies
See: Characteristics of included studies, Characteristics of excluded studies, Characteristics of ongoing studies.
Results of the search
We identified 4122 records from database searching and 155 additional records from other sources in 2016. The searches yielded a total of 3783 records after de‐duplication; only 57 full‐text articles remained after title and abstract screening. Finally, we excluded all 57 full‐text articles because they did not meet the inclusion criteria after we screened the full text. There were no new studies included in this update of the review. From the records identified in the previous versions of this review, six randomised trials of endarterectomy plus medical treatment versus medical treatment alone for symptomatic carotid stenosis were identified: we included three (ECST 1998; NASCET 1991; VACSP 1991), excluded two (Fields 1968; Shaw 1984), and one was an ongoing study in Europe (ISRCTN97744893). See Figure 1.
Study flow diagram
Included studies
We identified and included three relevant randomised studies (ECST 1998; NASCET 1991; VACSP 1991). Because of re‐measurements of the degree of carotid stenosis and certain other baseline clinical characteristics, and changes in the definitions of outcome events, the data reported below differ slightly from the original trial reports. Individual patient data were available for all 6092 participants randomised and included in the final analysis of the three original trials. Of these, one participant in the VACSP 1991 trial had no follow‐up data at the time the trial was stopped, nine ECST 1998 participants had an occlusion of the symptomatic carotid artery on the pre‐randomisation angiogram, and the degree of stenosis was unknown in one ECST 1998 participant. We did not include these cases in the analyses of the effect of surgery by stenosis group. Thus, we included 6081 (99.8%) participants in the analyses of the effect of surgery stratified into the pre‐specified stenosis groups. Mean follow‐up was 65 months (standard deviation (SD) = 34, range = 1 day to 167 months), giving a total of 35,000 patient‐years of follow‐up, with 1711 stroke outcomes in 1265 participants.
At the outset of NASCET 1991, of those participants in the medical arm, 16% were on lipid‐lowering drugs, 60% on antihypertensive medication, and 98% on antithrombotic medication (45% on aspirin of less than 650 mg/day, 38% on aspirin of at least 650 mg/day, 17 on other medication). In ECST 1998, the proportions on medication for at least 50% of follow‐up visits were 79% for aspirin, 18% for other antithrombotic drugs, 8% for anticoagulants, and 8% for lipid‐lowering drugs. In neither trial did medication use differ significantly between the randomised treatment groups.
Comparability of trial designs
The methods of the three included trials were very similar. Briefly, participants were recruited if they had suffered a recent carotid distribution TIA, a non‐disabling ischaemic stroke, or a retinal infarction, and had a stenosis of the ipsilateral (symptomatic) carotid artery. Prior to randomisation, each trial required that potential participants were seen by a neurologist or a stroke physician to confirm their eligibility, and ensure that the symptomatic carotid artery (and preferably the contralateral carotid artery and intracranial circulation) was imaged by angiography (usually selective catheter angiography). Treatment (immediate carotid endarterectomy plus best medical treatment versus best medical treatment alone) was allocated by central telephone randomisation, stratified by centre. Follow‐up was performed at pre‐specified intervals by a neurologist or a stroke physician.
ECST 1998 recruited from 100 centres in 14 European countries, NASCET 1991 from 106 centres, mainly in the USA and Canada, but including some centres in Europe, Israel, South Africa, and Australia, and the VACSP 1991 trial, which recruited from 16 Veterans Affairs medical centres in the USA. Although the trial designs were similar, there were some differences in methods between ECST 1998 and NASCET 1991, and between these trials and the VACSP 1991 trial:
-
the VACSP 1991 trial recruited only men; ECST 1998 and NASCET 1991 included both sexes;
-
time from the last cerebrovascular event to randomisation had to be less than four months in the VACSP 1991 trial and in NASCET 1991 (changed to six months after 1991), and less than six months in ECST 1998;
-
inclusion and exclusion in ECST 1998 were based on the 'uncertainty principle', whereas NASCET 1991 and VACSP 1991 had specified criteria. Thus, people with any degree of carotid stenosis could be randomised or treated outside the trial at the discretion of the physician in ECST 1998, whereas the NASCET 1991 and VACSP 1991 trials intended only to recruit people with greater than 30% and greater than 50% stenosis, respectively;
-
participants were randomised in a 50:50 ratio in the NASCET 1991 and VACSP 1991 trials, and in a 60:40 (surgery:no surgery) ratio in ECST 1998;
-
the recommended dose of aspirin was 1300 mg in NASCET 1991, 325 mg in the VACSP 1991 trial, and unspecified in ECST 1998;
-
follow‐up was at one, three, six, nine, and 12 months, and every four months thereafter in NASCET 1991, at four and 12 months, and annually thereafter in ECST 1998, and at one and three months, and every six months thereafter in the VACSP 1991 trial.
Reassessment of carotid angiograms
We re‐measured the degree of carotid stenosis by the method used in the NASCET 1991 and the VACSP 1991 trials on the 3018 angiograms from ECST 1998 participants in the previous version of this review (Rerkasem 2011). The relationship between the ECST 1998 and the NASCET 1991 and VACSP 1991 measurements was linear above 30% stenosis, and they were highly correlated (Correlation coefficiency = 0.94, P < 0.00001), but the ECST 1998 method produced higher values. For example, on average, 50% and 70% stenosis by the NASCET 1991 and VACSP 1991 method were equivalent to 65% and 82% stenosis, respectively, by the ECST 1998 method. Near‐occlusion with post‐stenotic narrowing of the ICA presented in 262 participants (125 in ECST 1998 and 137 in NASCET 1991). Inter‐observer agreement between the ECST 1998 and NASCET 1991 radiologists in the allocation of the degree of stenosis into the standard categories (less than 30%, 30% to 49%, 50% to 69%, equal to or greater than 70%, near‐occlusion) was good (kappa = 0.70, 95% confidence interval (CI) 0.59 to 0.83, P < 0.0001), and there was no systematic bias between the two observers.
Participant characteristics
Each of the included studies randomised only people who had suffered a recent neurological event in the territory of a stenosed carotid artery. The qualifying events were non‐disabling strokes and TIAs, and were variously but sensibly defined. All three studies dealt with an elderly population, predominantly male. All three studies used explicit exclusion criteria, and in addition, ECST 1998 used the 'uncertainty principle'. The uncertainty principle refers to the state of equipoise relating to the intervention. If the patient's physician felt that the patient would clearly benefit, or clearly not benefit, from the surgery, the patient was excluded. Exclusion criteria in common between the studies were: severe coexisting medical disease; possible cardiac causes of emboli; major stroke; angiographic evidence of a second stenotic lesion in the surgically inaccessible portion above the level of the second cervical vertebra (also known as a tandem lesion); and prior ipsilateral carotid endarterectomy.
Comorbidities in the form of ischaemic heart disease, diabetes, hypertension, hypercholesterolaemia, and smoking were well represented among the participants. Participants included in the VACSP 1991 trial were all male and all had at least 50% symptomatic carotid stenosis. However, they were also less likely to have had a stroke as the presenting event than participants in the other two trials, and they tended to have more vascular risk factors than those in ECST 1998 and NASCET 1991. There were also some differences between ECST 1998 and NASCET 1991. For example, NASCET 1991 included more elderly people, and the median time from last symptoms to randomisation was less than in ECST 1998. However, the trial populations were otherwise broadly comparable.
Excluded studies
See Characteristics of excluded studies.
Two other randomised studies of carotid endarterectomy did not meet inclusion criteria. The first trial was a joint study of extracranial arterial disease. This included not only carotid endarterectomy, but also surgery of the aortic arch branches and vertebral arteries, in symptomatic and 'a few asymptomatic' people. A subgroup analysis of people with unilateral carotid disease undergoing carotid endarterectomy included 54% with vertebrobasilar symptoms (Fields 1968). The second trial reported on carotid endarterectomy done with the unusual adjunct of femorocarotid bypass and was stopped early because of high postoperative morbidity (Shaw 1984).
Ongoing studies
There was one ongoing trial: the second European Carotid Surgery trial (ECST‐2), which is an international randomised trial investigating the optimal treatment of people with symptomatic or asymptomatic moderate or severe carotid stenosis at low or intermediate risk of future stroke (ISRCTN97744893). The study compares the risks and benefits of treatment by modern optimised medical management alone versus the addition of immediate carotid surgery (or stenting) to optimised medical management. The trial has been recruiting participants since 2012.
Risk of bias in included studies
When applying Cochrane's tool for assessing risk of bias, we found that generally, all three included trials had adequate strategies to avoid bias, with the exception of VACSP 1991's method of allocation concealment (Higgins 2011; Figure 2; Figure 3). The Cochrane tool assesses the risk of bias of the study on six aspects: sequence generation, allocation concealment, blinding of participants, study personnel and outcome assessment, incomplete outcome data, selective outcome reporting, and other biases (Appendix 5).
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Allocation
All three included studies were randomised controlled trials with adequate generation of a randomised sequence. Allocation concealment was adequate except in VACSP 1991, where it was not clear whether allocation to groups was adequately concealed.
Blinding
Because of the nature of the intervention, none of these RCTs could be blinded for surgeons or participants. Each study made use of an independent external review process for all outcomes, but the clinical data presented for review were derived from the unblinded assessment discussed above, and may in theory, have been subject to bias.
Incomplete outcome data
Remarkably few participants were lost to follow‐up in any of these studies. The designs of the three RCTs are summarised in Characteristics of included studies. Each analysis was conducted on an intention‐to‐treat principle. A proportion of participants in each arm after randomisation ultimately received the treatment of the opposite assignment. Such surgical‐to‐medical crossover was usually because the participant declined surgery after randomisation. Medical‐to‐surgical crossovers occurred in a small proportion of participants in all studies. In NASCET 1991 and VACSP 1991, but not in ECST 1998, patient follow‐up data were censored at the time of medical‐to‐surgical crossover.
Selective reporting
ECST 1998 and NASCET 1991 were both stopped after appropriately pre‐specified interim analyses showed that the trial stopping rules had been met. VACSP 1991 was also stopped after the results of ECST 1998 and NASCET 1991 were announced, given that it was considered unethical to continue to randomise participants with severe stenosis. This sequence of events was entirely appropriate and is very unlikely to have introduced any bias into the results.
Other potential sources of bias
It appeared that the intervention itself was left to the discretion of the surgeon in each study. NASCET 1991 reported the frequency of different surgical techniques (use of patch and use of shunt).
Effects of interventions
See: Summary of findings for the main comparison Carotid endarterectomy for symptomatic carotid stenosis
Comparison of the results of the individual trials
Of the participants who were randomised to surgery, 1742/1807 underwent trial surgery in ECST 1998, 1415/1436 in NASCET 1991 and 91/91 in the VACSP 1991 trial. The median time from randomisation to trial surgery was two days in the VACSP 1991 trial, three days in NASCET 1991, and 14 days in ECST 1998. There was no significant difference between the trials in the operative risk of stroke and death (X² = 1.1, degrees of freedom (df) = 2, P = 0.6). There was a non‐significant trend towards higher operative stroke morbidity in participants with 50% to 69% stenosis in the ECST 1998 and VACSP 1991 trials compared with NASCET 1991, but there was no significant difference in operative mortality.
In each of the trials, some of the participants who were randomised to medical treatment had endarterectomy of the symptomatic carotid artery during follow‐up. This occurred in a total of 458 participants: 118/1211 (9.7%) in ECST 1998, 331/1449 (22.8%) in NASCET 1991, and 9/98 (9.2%) in the VACSP 1991 trial. The median (IQR) time from randomisation to such surgery was 536 (162 to 975) days in ECST 1998, 555 (217 to 963) days in NASCET 1991, and 79 (4 to 182) days in the VACSP 1991 trial. Surgery was performed most commonly in participants who had severe stenosis at randomisation: 33/114 (28.9%) near‐occlusions; 161/506 (31.8%) at least 70% stenosis without near‐occlusion; 132/721 (18.3%) 50% to 69% stenosis; 87/662 (13.1%) 30% to 49% stenosis; 44/751 (5.9%) less than 30% stenosis. The vast majority of these crossovers occurred after the announcement of benefit from surgery in participants with at least 70% stenosis by ECST 1998 and NASCET 1991 in 1991, and most of the participants who had less than 70% stenosis at baseline and who were subsequently operated upon had progressed to at least 70% stenosis by the time of surgery.
There were no significant differences between the trials in the risks of the main outcomes in any of the stenosis groups for either treatment group. There was also no significant heterogeneity between the trials in the effect of the randomised treatment allocation on the relative risks of any of the main outcomes in any of the stenosis groups. The effect of surgery on the relative risks of the main outcomes at five years of follow‐up is shown, along with the corresponding absolute risk reductions, by degree of stenosis for ECST 1998 and NASCET 1991 in the Data and analyses section. The results of the VACSP 1991 trial were also included, but were calculated at two years of follow‐up, because the trial was stopped early, before follow‐up was complete. The apparent lack of benefit from surgery in the VACSP 1991 trial compared with ECST 1998 and NASCET 1991 reflects the low risk of stroke in the medical treatment group at this early stage of follow‐up. The trend towards greater harm from surgery in the less than 30% stenosis group in ECST 1998 versus NASCET 1991, reflected the fact that a higher proportion of participants in this group in ECST 1998 had very mild (less than 10%) stenosis: 62% in ECST 1998 and 27% in NASCET 1991. However, in view of the lack of benefit of surgery in the less than 30% stenosis group as a whole, we did not do any further subdivision.
Analyses of pooled data
Since there were no significant differences between the trials, either in the risks of the study outcomes during follow‐up in the medical or surgical groups, or in the effects of surgery, we performed analyses on the pooled data. There were no imbalances in baseline characteristics between the surgery and medical groups in the original trials.
Of the 3334 participants who were randomised to surgery, 3248 (97.5%) underwent trial surgery. The median time from randomisation to trial surgery was six days. The median time from last symptoms to randomisation of NASCET 1991 was less than in ECST 1998. The median time from the last ischaemic event to randomisation was 36 days in NASCET 1991 and 45 days in ECST 1998. In NASCET 1991, the percentage of participants who were randomised within 30 days of event was 42% for the medical treatment group and 41% for the surgical treatment group.There were 229 strokes or deaths within 30 days of surgery (7.1%, 95% CI 6.3 to 8.1). There were no significant differences in surgical risk across the stenosis groups. The risk of death within 30 days of endarterectomy was 1.1% (36/3248, 95% CI 0.8 to 1.5), and the 30‐day case‐fatality for operative strokes was 9.6% (20/209, 95% CI 5.9 to 14.4).
There was no significant effect of surgery on the risk of death during follow‐up in any of the stenosis groups, in either the individual trials or the pooled data. The relative risks of each of the main study outcomes at five‐year follow‐up, derived from the pooled data, are shown in Analysis 1.1, Analysis 1.2, and Analysis 1.3. Surgery tended to be harmful in participants with less than 30% stenosis. In participants with 30% to 49% stenosis, the risks of each of the main outcomes were higher in the surgery group for the first two years of follow‐up. Thereafter, the risks were similar in both treatment groups, with no significant benefit from surgery for any of the main outcomes.
In participants with 50% to 69% stenosis, surgery was also associated with a higher risk of each of the main outcomes for the first two years of follow‐up, but this trend reversed during subsequent follow‐up, resulting in significant benefit from surgery for any stroke or operative death (number needed to treat to prevent one event at five years (NNTB) = 13, 95% CI 8 to 28)), and for ipsilateral carotid territory ischaemic stroke and operative stroke or death (NNTB = 22, 95% CI 12 to 80; Analysis 1.1). Benefit was non‐significant for disabling or fatal ipsilateral ischaemic, or operative stroke and death.
In participants with 70% to 99% stenosis without near‐occlusion, there was a highly significant reduction in the surgery group in the risks of each of the main outcomes. Benefit was apparent during the first year of follow‐up, reached a maximum by three years, and was still present at eight years. The NNTB to prevent one event at five years was 6 (95% CI 5 to 9) for ipsilateral carotid territory ischaemic stroke and operative stroke or death, and 14 (95% CI 8 to 35) for disabling or fatal ipsilateral ischaemic or operative stroke and operative death (Analysis 1.2; Analysis 1.3).
The results for participants with near‐occlusion were difficult to interpret because of relatively small numbers of patients and outcome events. However, there was no long‐term significant benefit from surgery for any of the main outcomes. The difference in the effectiveness of surgery between participants with near‐occlusion and participants with 70% or more stenosis without near‐occlusion was significant for each outcome: any stroke or operative death (Chi2 heterogeneity = 4.1, P = 0.04), ipsilateral carotid territory ischaemic stroke and operative stroke or death (Chi2 heterogeneity = 7.9, P = 0.005), and disabling or fatal ipsilateral ischaemic or operative stroke and operative death (Chi2 heterogeneity = 5.4, P = 0.02)
Although we presented results in the analyses using the fixed‐effect method, where I² > 0, we also analysed the data by using the random‐effects method; the results were similar.
Subgroup analyses
We did not include the VACSP 1991 trial in the subgroup analyses because the trial was confined to men and several other subgroup variables were unavailable for analysis. The remaining large trials included 95% of participants ever randomised to endarterectomy versus medical treatment for symptomatic carotid stenosis (ECST 1998; NASCET 1991). Individual patient data were available for all 5903 participants included in the final analysis of ECST 1998 and NASCET 1991. Of these, nine ECST 1998 participants had an occlusion of the symptomatic carotid artery on the pre‐randomisation angiogram, and the degree of stenosis was unknown in one ECST 1998 participant. We excluded these cases from our analyses, leaving 5893 (99.8%) participants. Mean follow‐up was 66 months (SD = 34, range = 1 day to 166 months), giving a total of 33,000 patient‐years of follow‐up.
Risk of ipsilateral stroke in the medical group
The risk of ipsilateral stroke in the medical group was significantly related to all of the subgroup variables, apart from contralateral ICA occlusion and smoking (Table 1). Among the predefined subgroups, the risk of ipsilateral ischaemic stroke decreased with time since the last event, increased with age, and was higher in men, in people presenting with hemispheric events than retinal events, in diabetics, and in people with irregular or ulcerated plaques.
| Subgroups | Ipsilaterial ischaemic stroke in medical group | |||
| HR | 95% CI (‐) | P | ||
| Predefined patient subgroups | ||||
| Sex (females versus males) | 0.79 | (0.64 to 0.97) | 0.03 | |
| Age | < 65 years | 1.00 | 0.001 | |
| 65 to 74 years | 1.23 | (1.00 to 1.51) | ||
| 75+ years | 1.70 | (1.28 to 2.56) | ||
| Time since last event | < 2 weeks | 1.00 | 0.003 | |
| 2 to 4 weeks | 0.80 | (0.61 to 1.06) | ||
| 4 to 12 weeks | 0.69 | (0.55 to 0.88) | ||
| > 12 weeks | 0.61 | (0.46 to 0.82) | ||
| Primary symptomatic event | Ocular only | 1.00 | < 0.001 | |
| Cerebral TIA | 1.88 | (1.38 to 2.55) | ||
| Stroke | 2.33 | (1.74 to 3.13) | ||
| Diabetes | 1.31 | (1.05 to 1.65) | 0.02 | |
| Irregular/ulcerated plaque | 1.35 | (1.11 to 1.64) | 0.003 | |
| Contralateral ICA occlusion | 1.30 | (0.09 to 1.88) | 0.16 | |
| Post‐hoc patient subgroups | ||||
| Duration of cerebral TIA | 1 hour or less | 1.00 | ||
| > 1 hour | 1.45 | (1.03 to 2.04) | 0.03 | |
| Previous TIA or stroke | 1.20 | (0.99 to 1.46) | 0.07 | |
| Myocardial infarction | 1.40 | (1.11 to 1.77) | 0.004 | |
| Angina | 1.26 | (1.02 to 1.56) | 0.03 | |
| Treated hypertension | 1.39 | (1.15 to 1.68) | 0.001 | |
| Treated hyperlipidaemia | 0.78 | (0.62 to 0.98) | 0.03 | |
| Smoking | 0.96 | (0.80 to 1.16) | 0.70 | |
ICA: internal carotid artery
TIA: transient ischaemic attack
Perioperative risk of stroke or death
Among the 3157 participants who underwent trial surgery, there were 222 operative strokes or deaths (7.0%, 95% CI 6.2 to 8.0). Among the predefined subgroups, the perioperative risk of stroke or death was higher in women (Analysis 2.1), and in people with hemispheric events, diabetes, contralateral carotid occlusion, and irregular or ulcerated plaques (Table 2). Among the post‐hoc subgroups, perioperative risk was reduced in people with angina, and increased in people with hypertension and with a previous TIA or stroke.
| Subgroups | Perioperative stroke or death in surgery group | |||
| HR | 95% CI (‐) | P | ||
| Predefined patient subgroups | ||||
| Sex (females versus males) | 1.50 | (1.14 to 1.97) | 0.004 | |
| Age | < 65 years | 1.00 | 0.78 | |
| 65 to 74 years | 0.99 | (0.76 to 1.32) | ||
| 75+ years | 0.83 | (0.49 to 1.41) | ||
| Time since last event | < 2 weeks | 1.00 | 0.69 | |
| 2 to 4 weeks | 1.22 | (0.78 to 1.90) | ||
| 4 to 12 weeks | 1.14 | (0.77 to 1.68) | ||
| > 12 weeks | 1.28 | (0.84 to 1.95) | ||
| Primary symptomatic event | Ocular only | 1.00 | < 0.001 | |
| Cerebral TIA | 2.62 | (1.68 to 4.09) | ||
| Stroke | 1.91 | (1.22 to 3.01) | ||
| Diabetes | 1.45 | (1.05 to 2.02) | 0.03 | |
| Irregular/ulcerated plaque | 1.37 | (1.03 to 1.82) | 0.03 | |
| Contralateral ICA occlusion | 2.21 | (1.33 to 3.67) | 0.002 | |
| Post‐hoc patient subgroups | ||||
| Duration of cerebral TIA | 1 hour or less | 1.00 | ||
| > 1 hour | 1.24 | (0.81 to 1.92) | 0.33 | |
| Previous TIA or stroke | 1.59 | (1.21 to 2.09) | 0.001 | |
| Myocardial infarction | 0.87 | (0.59 to 1.27) | 0.46 | |
| Angina | 0.67 | (0.47 to 0.97) | 0.03 | |
| Treated hypertension | 1.33 | (1.02 to 1.74) | 0.04 | |
| Treated hyperlipidaemia | 1.06 | (0.74 to 1.51) | 0.75 | |
| Smoking | 0.97 | (0.74 to 1.27) | 0.81 | |
ICA: internal carotid artery
TIA: transient ischaemic attack
Subgroup‐treatment effect modifiers
As in the original trials, the primary outcome for analyses of the effect of surgery was time‐to‐first ipsilateral ischaemic stroke in the territory of the symptomatic carotid artery, and any stroke or death that occurred within 30 days after trial surgery. Table 3 showed the significance of the tests of subgroup treatment effect modification in relative and absolute reductions in the risk of the primary outcome with surgery. Among the predefined subgroups, there was significant heterogeneity of risk reduction by each of the different tests in relation to sex, age, and time since last event. The overall patterns in treatment effect were consistent across the stenosis categories. For example, benefit from carotid endarterectomy in participants with 50% to 69% stenosis was significantly less in women (P = 0.04), fell significantly with increasing time since last event (P = 0.009), and tended to increase with age (P = 0.23). The three‐way interaction terms in the Cox model did not identify significant relationships between the treatment effect by subgroup interaction and degree of stenosis for any of the subgroups, although there were borderline significant trends that the effect of irregular plaque (P = 0.09) and primary symptomatic event (P = 0.08) on treatment effect was greater at higher degrees of stenosis. Benefit tended to be greatest in people with stroke, and to decline progressively in people with cerebral TIA and retinal events, in both the 50% to 69% and 70% to 99% stenosis groups. Analysis also showed a trend towards greater benefit in people with irregular plaque than a smooth plaque in both stenosis groups. However, these treatment effects by subgroup interactions still failed to reach significance when the analysis was restricted to people with 50% to 99% stenosis: P = 0.06 for irregular plaque, and P = 0.1 for primary symptomatic events.
| Effect of surgery on the risk of the primary outcome (P value) | |||
| Relative risk reduction | Absolute reduction in 5‐year actuarial risk | ||
| Cox model | 5‐year actuarial risk | ||
| Predefined patient subgroups | |||
| Sex | 0.007 | 0.008 | 0.003 |
| Age groups | 0.09 | 0.04 | 0.03 |
| Time since last event groups | 0.04 | 0.05 | 0.009 |
| Primary symptomatic event | 0.21 | 0.30 | 0.16 |
| Diabetes | 0.51 | 0.85 | 0.63 |
| Irregular/ulcerated plaque | 0.58 | 0.23 | 0.10 |
| Contralateral ICA occlusion | 0.30 | 0.34 | 0.25 |
| Post‐hoc subgroups | |||
| Duration of cerebral TIA | 0.44 | 0.47 | 0.42 |
| Previous TIA or stroke | 0.08 | 0.23 | 0.50 |
| Myocardial infarction | 0.06 | 0.02 | 0.01 |
| Angina | 0.08 | 0.11 | 0.06 |
| Treated hypertension | 0.19 | 0.29 | 0.09 |
| Treated hyperlipidaemia | 0.63 | 0.85 | 0.85 |
| Smoking | 0.40 | 0.40 | 0.38 |
ICA: internal carotid artery
TIA: transient ischaemic attack
No subgroup‐treatment effect interaction term was significant at the P < 0.01 level set for the post‐hoc subgroups.
To assess the consistency of the effects of sex, age, and time since last event on the benefit of carotid endarterectomy, we analysed ECST 1998 and NASCET 1991 separately for people with 50% to 99% stenosis. Both trials showed the same patterns. For participants with 50% to 99% stenosis, the estimates of the number of people needed to undergo surgery to prevent one ipsilateral stroke in five years from the pooled data were nine for men versus 36 for women, five for age 75 years or older versus 18 for age less than 65 years, and five for people randomised within two weeks versus 125 for people randomised more than 12 weeks (10 and 18 for people randomised two to four weeks and four to 12 weeks, respectively).
Discussion
Summary of main results
Benefit of surgery in relation to degree of carotid stenosis
With the exception of near‐occlusions, the degree of stenosis above which surgery is beneficial was shown to be 50% (by the measurement used in the NASCET 1991 and VACSP 1991 trials: equivalent to about 65% stenosis by the method used in ECST 1998). Benefit in people with 50% to 69% stenosis became more modest with longer duration of follow‐up. Lack of benefit for moderate stenosis in the original ECST 1998 report is not inconsistent with this, but reflects the differences between the analyses in the measurement of stenosis and the definition of outcome events. The re‐analysis of individual patient data has shown that the effects of surgery in ECST 1998 and NASCET 1991 in people with 50% to 69% stenosis were consistent.
It is possible that the intention‐to‐treat analysis may have underestimated the benefit of endarterectomy in the near‐occlusions because of the relatively high rate of endarterectomy during follow‐up in the medical treatment group in NASCET 1991. However, the rate of endarterectomy was the same in the participants with 70% to 99% stenosis without near‐occlusion, and yet there was considerable benefit by intention‐to‐treat analysis in this group. Moreover, there was no benefit from surgery in the near‐occlusion group in ECST 1998, where the rate of endarterectomy in the medical group was lower than in NASCET 1991. The confidence intervals around the estimates of treatment effect in the near‐occlusions were wide, but the difference in the effect of surgery between this group and people with 70% to 99% stenosis without near‐occlusion was significant for each of the three main outcomes. Some people may still wish to undergo surgery, particularly if they experience recurrent TIAs, but they should be informed that the benefit from endarterectomy in preventing a stroke is likely to be modest in the short‐term and unknown in the long‐term.
Overall completeness and applicability of evidence
Operative risk
The 7% operative risk of stroke and death within 30 days of endarterectomy included any stroke (ocular or cerebral) with symptoms lasting longer than 24 hours. It is consistent with surgical case‐series in which patients were also assessed post‐operatively by a neurologist. The benefits of surgery outlined above will only be obtained in routine clinical practice if the operative risk is similarly low. Since it is likely that minor strokes are regularly missed in routine clinical practice outside strictly organised clinical trials, an audit of operative risk should be performed by an independent neurologist or stroke physician (Bond 2004). The 30‐day case‐fatality for operative stroke in the pooled analysis was 9.6% (95% CI 5.9 to 14.4), and the ratio of non‐fatal to fatal operative strokes was 10:1. The possibility that non‐fatal strokes have been missed should be considered in any surgical audit in which the ratio of non‐fatal to fatal outcomes is lower.
Subgroup analyses
The pooled analysis of ECST 1998 and NASCET 1991 found three significant and clinically important subgroup treatment effect modifiers among the predefined subgroup variables. Benefit from surgery was greater in men than in women, and in the elderly, and benefit decreased with time since the last symptoms. These observations were consistent across the 50% to 69% and 70% to 99% stenosis groups, and across the two trials. Taken with other evidence discussed below, these subgroup observations were sufficiently robust to be used to guide the use of carotid endarterectomy in routine clinical practice.
In most trials of treatments for vascular disease, such as trials of blood‐pressure lowering or lipid lowering therapies, the effects of risk factors on the main outcome events are qualitatively similar in the treatment and control groups. The analysis of subgroup effects in the case of carotid endarterectomy is more complicated because the overall effect of surgery is determined by the balance of two different outcomes (ipsilateral carotid territory ischaemic stroke on medical treatment versus the perioperative risk of stroke or death within 30 days of carotid endarterectomy), which have very different mechanisms. Therefore, particular risk factors might have qualitatively different effects on each outcome. This was the case in our analysis for sex, increasing age, and decreasing time from last event to randomisation.
Women had a lower risk of ipsilateral ischaemic stroke on medical treatment and a higher operative risk in comparison with men. These same patterns have also been shown in the two large trials of carotid endarterectomy for asymptomatic stenosis (ACAS 1995; ACST 2004). Carotid endarterectomy is very clearly beneficial in women with 70% to 99% symptomatic stenosis, but not in women with 50% to 69% stenosis. Whether surgery is still indicated in individual women will depend on the balance of their other risk factors.
It could be argued that the increased benefit from surgery in people over 75 years old might not be generalisable to routine clinical practice, because trial participants generally have a good prognosis, and elderly people might have a greater operative risk in clinical practice (Bond 2005). However, there is no justification for withholding carotid endarterectomy in people over 75 years old who are deemed to be medically fit to undergo surgery. The subgroup analyses of ECST 1998 and NASCET 1991 indicated that benefit was likely to be greatest in this group, because of their high risk of stroke on medical treatment, although it is important to note that the trials included very few participants over the age of 80 years.
The urgency with which carotid endarterectomy should be performed has been much debated. The risk of stroke on medical treatment after a TIA or minor stroke falls rapidly over the subsequent year, possibly because of the 'healing' of the unstable atheromatous plaque or an increase in collateral blood flow to the symptomatic hemisphere, but there have been no reliable data on the extent to which the effectiveness of carotid endarterectomy also falls with time. There has been concern that the operative risk may be increased if surgery is performed early, particularly in people with major cerebral infarction or stroke‐in‐evolution (Rerkasem 2009). For neurologically stable people, such as those enrolled in the trials, benefit from carotid endarterectomy was greatest in those randomised within two weeks of their last event, and fell rapidly with increasing delay. However, the vast majority of people who undergo carotid endarterectomy for symptomatic stenosis in Europe and North America are currently being operated on more than two weeks after their presenting event, and many are operated on more than 12 weeks after the event, when benefit is considerably reduced in people with 70% to 99% stenosis, and absent in those with 50% to 69% stenosis (Rothwell 2004).
Quality of the evidence
Generally, the three included trials had adequate strategies to avoid bias in their study except VACSP 1991, which did not provide information on allocation concealment. Analysis of individual patient data has advantages over meta‐analysis of overall trial results, and was essential for the endarterectomy trials. Differences between the trials in the method of measurement of carotid stenosis and in the definition of outcome events made it impossible to combine tabular results satisfactorily. By re‐analysing the individual patient data and reassessing the carotid angiograms we showed that the results of ECST 1998 and NASCET 1991 were consistent, removing the uncertainty that was generated by the apparent disparities between the originally reported results of the trials. In summary, the quality of the evidence for near occlusion and less than 30% of carotid stenosis is high. The quality of the evidence for 50% to 99% of carotid stenosis is moderate for any stroke or operative death as well as ipsilateral ischaemic stroke and any operative stroke or death outcome.
Potential biases in the review process
The dangers of subgroup analysis, particularly the selective reporting of multiple post‐hoc analyses, are well documented. However, we believe that the subgroup analyses of the pooled data from ECST 1998 and NASCET 1991 were reliable. We chose the predefined analyses prior to pooling the trial data, and we reported all of the analyses that we performed. Significance testing was based on the overall interaction of the subgroup variable with the treatment effect, rather than the significance of the treatment effect within each subgroup category. Statistical tests of subgroup‐treatment effect interaction terms were conservative, and a P value < 0.1 is generally regarded as significant. However, to reduce the risk of chance findings, P < 0.05 was required for predefined subgroups and P < 0.01 for post‐hoc subgroups. It was also fortunate to have two major trials with very similar methods, and therefore, to be able to assess the consistency of observations in two completely independent studies. Indeed, the consistency in the subgroup effects between the trials was more convincing than the statistical significance of the overall effects.
Agreements and disagreements with other studies or reviews
In 2012, a systematic review was carried out to compare long‐term rates of stroke or death for carotid endarterectomy plus medical treatment versus medical therapy alone, in people suffering from carotid artery stenosis (Guay 2012). This systematic review included evidence up to August 2011. For symptomatic carotid stenosis, ECST 1998 and NASCET 1991 were included. The review reported that for people with symptomatic carotid stenosis (50% to 99% NASCET 1991), there was a significantly lower risk of stroke or death among people who had carotid endarterectomy plus medical treatment compared with people who received medical treatment alone from two to five years of follow‐up (relative risk 0.69, 95% CI 0.59 to 0.81). The number needed to treat for a beneficial outcome was 11 patients (95% CI 8 to 17). For people without stenosis (less than 50% stenosis), there was no significant differences in the risk of stroke or death between the two groups. These results are similar to the findings in our review.
In 2015, a systematic review was performed of all available guidelines for the treatment of carotid artery stenosis, published in any language between 1 January 2008 and 28 January 2015. There were 33 guidelines for symptomatic carotid stenosis. Thirty‐one of these guidelines (94%) recommended that carotid endarterectomy should be performed in people with average risk symptomatic carotid stenosis of 50% to 99% (Abbott 2015). The remaining two guidelines did not recommend carotid endarterectomy for all symptomatic carotid stenosis, because of a limited number of surgeons with high volume experience in carotid endarterectomy. To some extent, they also preferred carotid artery stenting to carotid endarterectomy (Bladin 2011; Liu 2012).
Study flow diagram
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Comparison 1 Surgery versus no surgery, Outcome 1 Any stroke or operative death.
Comparison 1 Surgery versus no surgery, Outcome 2 Ipsilateral ischaemic stroke and any operative stroke or death.
Comparison 1 Surgery versus no surgery, Outcome 3 Disabling or fatal ipsilateral ischaemic or operative stroke and death.
Comparison 2 Subgroup analyses (5‐year cumulative risk of ipsilateral carotid ischaemic stroke, and any stroke or death within 30 days after surgery, according to 3 variables in patients with > 50% carotid stenosis in ECST and NASCET), Outcome 1 Sex.
Comparison 2 Subgroup analyses (5‐year cumulative risk of ipsilateral carotid ischaemic stroke, and any stroke or death within 30 days after surgery, according to 3 variables in patients with > 50% carotid stenosis in ECST and NASCET), Outcome 2 Age (years).
Comparison 2 Subgroup analyses (5‐year cumulative risk of ipsilateral carotid ischaemic stroke, and any stroke or death within 30 days after surgery, according to 3 variables in patients with > 50% carotid stenosis in ECST and NASCET), Outcome 3 Time since last event (weeks).
| Carotid endarterectomy for symptomatic carotid stenosis | ||||||
| Patients or population: people with carotid stenosis and recent transient ischaemic attacks (TIA) or minor ischaemic strokes in the territory of that artery Settings: in hospitals with carotid centres1 Intervention: best medical therapy with carotid surgery2,3 Comparison: best medical therapy without carotid surgery2 | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | Number of (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Best medical treatment alone | Best medical treatment with carotid surgery | |||||
| Any stroke or operative death | Near occlusion | RR 0.95 (0.59 to 1.53) | 271 (2 studies) | ++++ High4 | None of these RCTs could be blinded for surgeons or patients due to the nature of the intervention. | |
| 22 per 100 | 20 per 100 | |||||
| 70% to 99% carotid stenosis | RR 0.53 (0.42 to 0.67) | 1095 (3 studies) | +++Ο Moderate5 | |||
| 29 per 100 | 15 per 100 | |||||
| 50% to 69% carotid stenosis | RR 0.77 (0.63 to 0.94) | 1549 (3 studies) | +++Ο Moderate5 | |||
| 23 per 100 | 18 per 100 | |||||
| 30% to 49% carotid stenosis | RR 0.97 (0.79 to 1.19) | 1429 (2 studies) | ++++ High4 | |||
| 21 per 100 | 20 per 100 | |||||
| < 30% carotid stenosis | RR 1.25 (0.99 ‐ 1.56) | 1746 (2 studies) | ++++ High4 | |||
| 14 per 100 | 17 per 100 | |||||
| Ipsilateral ischaemic stroke, and any operative stroke or death | Near occlusion | RR 1.03 (0.57 to 1.84) | 271 (2 studies) | ++++ High4 | None of these RCTs could be blinded for surgeons or patients due to the nature of the intervention. | |
| 15 per 100 | 15 per 100 | |||||
| 70% to 99% carotid stenosis | RR 0.47 (0.25 to 0.88) | 1095 (3 studies) | +++Ο Moderate5 | |||
| 23 per 100 | 10 per 100 | |||||
| 50% to 69% carotid stenosis | RR 0.84 (0.60 to 1.18) | 1549 (3 studies) | +++Ο Moderate5 | |||
| 15 per 100 | 12 per 100 | |||||
| 30% to 49% carotid stenosis | RR 0.93 (0.62 to 1.38) | 1429 (2 studies) | ++++ High4 | |||
| 15 per 100 | 13 per 100 | |||||
| < 30% carotid stenosis | RR 1.27 (0.80 to 2.01) | 1746 (2 studies) | ++++ High4 | |||
| 9 per 100 | 11 per 100 | |||||
| *The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the intervention group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) | ||||||
| 1 ECST recruited from 100 centres in 14 European countries, NASCET from 106 centres mainly in the USA and Canada, but including some centres in Europe, Israel, South Africa and Australia, and the VACSP trial from 16 Veterans Affairs medical centres in the USA 2 The recommended dose of aspirin for best medical treatment was 1300 mg in NASCET, 325 mg in the VACSP trial, and unspecified in ECST 3 The median time from randomisation to trial surgery was two days in the VACSP trial, three days in NASCET and 14 days in ECST. 4 All 2 studies (ECST, NASCET) are unconfounded truly randomised controlled trials and conducted on an intention to treat principle with adequate concealment, Few patients were lost to follow up in any of these studies (follow up 99.8‐100%) 5 All 3 studies (ECST, NASCET, VACSP) are unconfounded truly randomised controlled trials and conducted on an intention‐to‐treat principle. However, the allocation concealment was not described in one trial (VACSP). In addition, ECST and NASCET were both stopped after appropriately pre‐specified interim analyses showed that the trial stopping rules had been met. VACSP was also stopped with 193 participants after the results of ECST and NASCET were announced. | ||||||
| Subgroups | Ipsilaterial ischaemic stroke in medical group | |||
| HR | 95% CI (‐) | P | ||
| Predefined patient subgroups | ||||
| Sex (females versus males) | 0.79 | (0.64 to 0.97) | 0.03 | |
| Age | < 65 years | 1.00 | 0.001 | |
| 65 to 74 years | 1.23 | (1.00 to 1.51) | ||
| 75+ years | 1.70 | (1.28 to 2.56) | ||
| Time since last event | < 2 weeks | 1.00 | 0.003 | |
| 2 to 4 weeks | 0.80 | (0.61 to 1.06) | ||
| 4 to 12 weeks | 0.69 | (0.55 to 0.88) | ||
| > 12 weeks | 0.61 | (0.46 to 0.82) | ||
| Primary symptomatic event | Ocular only | 1.00 | < 0.001 | |
| Cerebral TIA | 1.88 | (1.38 to 2.55) | ||
| Stroke | 2.33 | (1.74 to 3.13) | ||
| Diabetes | 1.31 | (1.05 to 1.65) | 0.02 | |
| Irregular/ulcerated plaque | 1.35 | (1.11 to 1.64) | 0.003 | |
| Contralateral ICA occlusion | 1.30 | (0.09 to 1.88) | 0.16 | |
| Post‐hoc patient subgroups | ||||
| Duration of cerebral TIA | 1 hour or less | 1.00 | ||
| > 1 hour | 1.45 | (1.03 to 2.04) | 0.03 | |
| Previous TIA or stroke | 1.20 | (0.99 to 1.46) | 0.07 | |
| Myocardial infarction | 1.40 | (1.11 to 1.77) | 0.004 | |
| Angina | 1.26 | (1.02 to 1.56) | 0.03 | |
| Treated hypertension | 1.39 | (1.15 to 1.68) | 0.001 | |
| Treated hyperlipidaemia | 0.78 | (0.62 to 0.98) | 0.03 | |
| Smoking | 0.96 | (0.80 to 1.16) | 0.70 | |
| ICA: internal carotid artery | ||||
| Subgroups | Perioperative stroke or death in surgery group | |||
| HR | 95% CI (‐) | P | ||
| Predefined patient subgroups | ||||
| Sex (females versus males) | 1.50 | (1.14 to 1.97) | 0.004 | |
| Age | < 65 years | 1.00 | 0.78 | |
| 65 to 74 years | 0.99 | (0.76 to 1.32) | ||
| 75+ years | 0.83 | (0.49 to 1.41) | ||
| Time since last event | < 2 weeks | 1.00 | 0.69 | |
| 2 to 4 weeks | 1.22 | (0.78 to 1.90) | ||
| 4 to 12 weeks | 1.14 | (0.77 to 1.68) | ||
| > 12 weeks | 1.28 | (0.84 to 1.95) | ||
| Primary symptomatic event | Ocular only | 1.00 | < 0.001 | |
| Cerebral TIA | 2.62 | (1.68 to 4.09) | ||
| Stroke | 1.91 | (1.22 to 3.01) | ||
| Diabetes | 1.45 | (1.05 to 2.02) | 0.03 | |
| Irregular/ulcerated plaque | 1.37 | (1.03 to 1.82) | 0.03 | |
| Contralateral ICA occlusion | 2.21 | (1.33 to 3.67) | 0.002 | |
| Post‐hoc patient subgroups | ||||
| Duration of cerebral TIA | 1 hour or less | 1.00 | ||
| > 1 hour | 1.24 | (0.81 to 1.92) | 0.33 | |
| Previous TIA or stroke | 1.59 | (1.21 to 2.09) | 0.001 | |
| Myocardial infarction | 0.87 | (0.59 to 1.27) | 0.46 | |
| Angina | 0.67 | (0.47 to 0.97) | 0.03 | |
| Treated hypertension | 1.33 | (1.02 to 1.74) | 0.04 | |
| Treated hyperlipidaemia | 1.06 | (0.74 to 1.51) | 0.75 | |
| Smoking | 0.97 | (0.74 to 1.27) | 0.81 | |
| ICA: internal carotid artery | ||||
| Effect of surgery on the risk of the primary outcome (P value) | |||
| Relative risk reduction | Absolute reduction in 5‐year actuarial risk | ||
| Cox model | 5‐year actuarial risk | ||
| Predefined patient subgroups | |||
| Sex | 0.007 | 0.008 | 0.003 |
| Age groups | 0.09 | 0.04 | 0.03 |
| Time since last event groups | 0.04 | 0.05 | 0.009 |
| Primary symptomatic event | 0.21 | 0.30 | 0.16 |
| Diabetes | 0.51 | 0.85 | 0.63 |
| Irregular/ulcerated plaque | 0.58 | 0.23 | 0.10 |
| Contralateral ICA occlusion | 0.30 | 0.34 | 0.25 |
| Post‐hoc subgroups | |||
| Duration of cerebral TIA | 0.44 | 0.47 | 0.42 |
| Previous TIA or stroke | 0.08 | 0.23 | 0.50 |
| Myocardial infarction | 0.06 | 0.02 | 0.01 |
| Angina | 0.08 | 0.11 | 0.06 |
| Treated hypertension | 0.19 | 0.29 | 0.09 |
| Treated hyperlipidaemia | 0.63 | 0.85 | 0.85 |
| Smoking | 0.40 | 0.40 | 0.38 |
| ICA: internal carotid artery | |||
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Any stroke or operative death Show forest plot | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 1.1 Near occlusion | 2 | 271 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.95 [0.59, 1.53] |
| 1.2 70% to 99% | 3 | 1095 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.53 [0.42, 0.67] |
| 1.3 50% to 69% | 3 | 1549 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.77 [0.63, 0.94] |
| 1.4 30% to 49% | 2 | 1429 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.97 [0.79, 1.19] |
| 1.5 < 30% | 2 | 1746 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.25 [0.99, 1.56] |
| 2 Ipsilateral ischaemic stroke and any operative stroke or death Show forest plot | 3 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
| 2.1 Near occlusion | 2 | 271 | Risk Ratio (M‐H, Random, 95% CI) | 1.03 [0.57, 1.84] |
| 2.2 70% to 99% | 3 | 1095 | Risk Ratio (M‐H, Random, 95% CI) | 0.47 [0.25, 0.88] |
| 2.3 50% to 69% | 3 | 1549 | Risk Ratio (M‐H, Random, 95% CI) | 0.84 [0.60, 1.18] |
| 2.4 30% to 49% | 2 | 1429 | Risk Ratio (M‐H, Random, 95% CI) | 0.93 [0.62, 1.38] |
| 2.5 < 30% | 2 | 1746 | Risk Ratio (M‐H, Random, 95% CI) | 1.27 [0.80, 2.01] |
| 3 Disabling or fatal ipsilateral ischaemic or operative stroke and death Show forest plot | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 3.1 Near occlusion | 2 | 271 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.29 [0.51, 3.27] |
| 3.2 70% to 99% | 3 | 1095 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.40 [0.26, 0.64] |
| 3.3 50% to 69% | 2 | 1502 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.73 [0.46, 1.15] |
| 3.4 30% to 49% | 2 | 1429 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.96 [0.60, 1.54] |
| 3.5 < 30% | 2 | 1746 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.72 [0.99, 2.96] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Sex Show forest plot | 2 | Risk Difference (M‐H, Fixed, 95% CI) | Subtotals only | |
| 1.1 Men | 2 | 1886 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.10 [‐0.13, ‐0.06] |
| 1.2 Women | 2 | 832 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.03 [‐0.07, 0.02] |
| 2 Age (years) Show forest plot | 2 | Risk Difference (M‐H, Fixed, 95% CI) | Subtotals only | |
| 2.1 < 65 | 2 | 1281 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.05 [‐0.09, ‐0.01] |
| 2.2 65 to 74 | 2 | 1143 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.07 [‐0.12, ‐0.03] |
| 2.3 > 75 | 2 | 294 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.17 [‐0.26, ‐0.09] |
| 3 Time since last event (weeks) Show forest plot | 2 | Risk Difference (M‐H, Fixed, 95% CI) | Subtotals only | |
| 3.1 < 2 | 2 | 624 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.17 [‐0.24, ‐0.11] |
| 3.2 2 to 4 | 2 | 483 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.09 [‐0.15, ‐0.02] |
| 3.3 4 to 12 | 2 | 1058 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.05 [‐0.09, ‐0.01] |
| 3.4 > 12 | 2 | 553 | Risk Difference (M‐H, Fixed, 95% CI) | 0.00 [‐0.06, 0.06] |
